recent advances in osteoporosis
TRANSCRIPT
![Page 1: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/1.jpg)
Recent Advances in Osteoporosis
DR ADRIJA HAJRA 1ST YEAR PGT
GENERAL MEDICINE,IPGME&R
![Page 2: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/2.jpg)
Osteoporosis, a condition characterized by decreased bone strength, is prevalent among postmenopausal women but also occurs inmen and women with underlying conditions or major risk factors associated with bone demineralization. Its chief clinical manifestationsare vertebral and hip fractures, although fractures can occur at any skeletal site.
![Page 3: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/3.jpg)
• Affects 50% of women over 50 years of age and 20% of all men
• People with vertebral fracture have close to 20% risk of a second fracture within the first year.
• For women, risk of suffering a hip fracture in her lifetime is about 17%
![Page 4: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/4.jpg)
![Page 5: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/5.jpg)
• 50 million people in India are osteoporotic or have low bone mass,
according to 2013 Asia-Pacific Regional Audit of International
Osteoporosis foundation reports..
• In 2012, European Medicines Agency and later in 2013 US FDA
advisory panel, recommended against the use of calcitonin salmon
for treatment of osteoporosis in women greater than 5 years after
menopause.
• In early 2014, European Medicines Agency’s Pharmacovigilance Risk
Assessment Committee recommended that strontium ranelate no
longer be used to treat osteoporosis.
5
![Page 6: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/6.jpg)
RISK FACTORS FOR OSTEOPOROSIS
![Page 7: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/7.jpg)
Bone remodeling
• coordinated resorption and formation of bone in basic multicellular units.– Bone is renewed in small units
• Temporally regulated.• Process similar in both cortical and trabecular
bone.
• More active in trabecular bone.• Occurs throught out life
![Page 8: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/8.jpg)
![Page 9: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/9.jpg)
Coupling and balanced
• Process of osteoblasts appearing at sites vacated by osteoclasts.
• In young adults, remodeling cycles tightly coupled.
• Thereby new bone formation almost equals bone resorption.
Bone resorption greater than new bone formation in menopausal women.
![Page 10: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/10.jpg)
![Page 11: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/11.jpg)
![Page 12: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/12.jpg)
Therapies for osteoporosis
• Anti-resorptive therapy– Slow down absorption action on osteoclasts
• Bisphosphonates,• denozumab,cathepsin K inhibitors• Raloxifene, strontium
• Anabolic therapy– Stimulate bone formation action on osteoblasts
• Parathormone, teriparatide• Wnt inhibitors,
![Page 13: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/13.jpg)
Currently FDA approved medications for treatment of osteoporosis
13
![Page 14: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/14.jpg)
Bisphosphonates
• Synthetic analogs of naturally occuring pyrophosphates.
• Nitrogen containing groups • Oral absorption very low 0.6% to 1.5%• 40 – 60 % of dose binds to bone, no
substantial affinity to other organs. • Remaining dose excreted unchanged in urine.
![Page 15: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/15.jpg)
• reduce the incidence of vertebral fractures by 40–50% in women known to have osteoporosis ,
• with similar reductions in nonvertebral fractures .
• to reduce the risk of hip fractures by 40–60% in women with severe osteoporosis
• men and patients with glucocorticoid-induced osteoporosis (GIOP), have shown that bisphosphonates confer similar benefits in and reduced vertebral fracture risk
![Page 16: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/16.jpg)
![Page 17: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/17.jpg)
![Page 18: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/18.jpg)
Mode of action
• Uptake by osteoclasts• inhibit a key enzyme in the mevalonic acid pathway,
farnesyl pyrophosphate synthase.• blocks prenylation (posttranslational modification) of small GTPases, such as Ras, Rho, and Rac.• signaling molecules in key osteoclastic functions
--maintenance of the cytoskeleton and --ruffled border formation
Leads to osteoclast apoptosis
![Page 19: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/19.jpg)
Monitering response to bisphosphonates
• Bone mineral Density– No change in BMD is also considered an
acceptable outcome • fracture risk not completely eliminated
![Page 20: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/20.jpg)
Anabolic agents
• Enhance bone formation– Increase in osteoblast number
• BMP and WNT– Enhance the function of mature osteoblasts
• IGF 1
• Parathormone does both
![Page 21: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/21.jpg)
Parathormone
• Trabecular bone volume, connectivity, bone microarchitecture were increased after treatment as well as biomechanical properties of bone.
• PTH appears to increase bone volume by increasing the number of bone trabeculae,.
• In humans, the anabolic effects of PTH on cortical bone are lower than in cancellous bone.
• induces IGF-I synthesis, inhibits sclerostin expression, and activates Wnt signaling
![Page 22: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/22.jpg)
![Page 23: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/23.jpg)
Reconstructed micro-QCT images of transiliac crest bone biopsies, taken before and after 21 months of teriparatide therapy, 20 μg/d.
Hodsman A B et al. Endocrine Reviews 2005;26:688-703
©2005 by Endocrine Society
![Page 24: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/24.jpg)
Reasons for strontium ranelate withdrawal
• Increased incidence of cardiac events and thromboembolism
• Serious skin reactions
• Liver inflammation
• Reduction in RBCs
• These risk did not justify the benefits that may accrue with strontium use.
24
![Page 25: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/25.jpg)
Reasons for calcitonin salmon withdrawal
• Risk of developing cancer was 2.4% higher in patients using calcitonin nasal spray compared with in those who took placebo.
25
![Page 26: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/26.jpg)
NEW MOLECULAR TARGET FOR OSTEOPOROSIS MANAGEMENT
26
![Page 27: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/27.jpg)
EMERGING THERAPIES
Anti body therapy:• Sclerostin Inhibitor – Romosozumab• RANKL inhibitor – Denosumab• DKK-1 inhibitor
Anti-seretonin therapyStem cells therapy:
• Mesenchymal Stem Cells• Hematopoietic Stem Cells
Cathepsin K inhibitors: Odanocatib
Biomaterials: • Chitosan biopolymers• Strontium – modified calcium phosphate cement (SrCPC)• Titanium
• Coated with Calcium phosphate• Coated with collagen type 1 • Polycaprolactone – magnesium composite• calcium phosphate/ silk scaffold
27
![Page 28: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/28.jpg)
Denosumab• Only anti-osteoporotic therapy approved in the past decade
which is still in use• Fully human monoclonal antibody that inhibits RANKL
(receptor activator of nuclear factor κβ ligand)• RANKL is a member of tumor necrosis factor family and is
expressed on surface of osteoblasts.• RANKL, by binding to RANK, which is present on surface of
osteoclast precursors, promotes the proliferation and differentiation of osteoclasts.
• Denosumab inhibits the interaction of RANKL and RANK, and acts to inhibit bone resorption.
28
![Page 29: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/29.jpg)
Denosumab
29
![Page 30: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/30.jpg)
![Page 31: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/31.jpg)
Denosumab
• Dosage: 60 mg dose by subcutaneous injection, every 6 months.
• Some rare reported side effects include – osteonecrosis of jaw– atypical fracture of femur
31
![Page 32: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/32.jpg)
Romosozumab• Humanized monoclonal antibody that inhibits sclerostin• Sclerostin is an osteocyte-derived inhibitor of osteoblastic activity• Sclerostin inhibition with romosozumab leads to immediate,
transient increases in bone formation markers and moderate sustained reduction in bone resorption markers
• Sclerostin gene is expressed only in skeletal tissue and the potential for systemic side effects is minimal
• Currently there are no data on anti-fracture efficacy and long term safety
• Romosozumab is presently in phase 3 trials administered by subcutaneous injection at monthly or 3 monthly intervals
32
![Page 33: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/33.jpg)
Romosozumab
33
![Page 34: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/34.jpg)
Odanatib
• Orally administered inhibitor of Cathepsin K• Cathepsin K is a major collagenase secreted by
osteoclasts to degrade organic bone matrix during bone remodeling process
• Currently in phase 2 clinical trial given at a dosage of 50 mg/wk
• Side effects like adverse skin reactions and sclerosis have been reported with its use
• Drug is not approved as of date
34
![Page 35: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/35.jpg)
Stem Cell Therapy
• Mesenchymal Stem cells, sourced from bone marrow, adipose tissue and cord blood have been studied.
• Easily available, devoid of ethical issues, possess immunosuppressant properties, are multipotent and are safe.
• MSCs differentiate into osteoblasts upon systemic administration
• Hematopoietic Stem Cells have also been found to produce osteoblasts.
35
![Page 36: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/36.jpg)
Gut seretonin inhibition
• Seretonin has catabolic action on bone• Most of body’s seretonin is derived from
enterochromaffin cells of gut• Inhibition of gut derived seretonin represents
a novel approach• Still in preclinical trials
36
![Page 37: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/37.jpg)
Dkk 1
• Gain of function mutation of Lrp5 increases bone mass.
• Glucocorticoids increase Dkk 1 levels
• Dkk 1 neutralisation causes increase in BMD in rodent models
• Human studies awaited.
![Page 38: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/38.jpg)
Bone Morphogenetic Protein
• TGF β superfamily• Broad family with actions on
chondrocytes,osteoblasts,osteoclasts.
• On osteoblasts lineage, leads to maturation of osteoblasts.( except BMP 3)
– Also have ability to induce osteoclastogenesis and have a potential for bone loss.
![Page 39: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/39.jpg)
Activin receptor
• BMP related protein• Mitogenic properties for cells of the osteoblastic
lineage, favors osteoblastogenesis, and enhances osteoclastogenesis
• BMP 3 acts through activin receptor• BMP 3 inhibits bone formation.• Soluble activin receptor fused to IgG-Fc can
decrease bone resorption and enhance bone formation
![Page 40: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/40.jpg)
IGF 1 and bone
• Mediates effect of GH on longitudinal bone growth.• In bone IGF 1 is PTH dependent.• Necessary to obtain anabolic response to PTH.• Enhances function of differentiated osteoblast Circulating IGF-I contributes to cortical bone integrity,• Skeletal IGF-I plays a more significant role in the
maintenance of trabecular bone integrity• Anorexia nervosa pts have low IGF 1 and low BMD
![Page 41: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/41.jpg)
Conclusion
Among the drugs discussed only denosumab is approved for use in US and Europe
India still awaits the availability of these molecules
Optimal use of available anti-resorptive therapies to manage osteoporosis and prevent its complications is hence required
41
![Page 42: Recent advances in osteoporosis](https://reader035.vdocuments.mx/reader035/viewer/2022062903/58a2bb461a28ab5d408b6d8f/html5/thumbnails/42.jpg)
42
Thank You